---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-003357"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2024-02-07T23:59:59+00:00"
generated_at: "2026-06-06T06:23:29.282363+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Joshua Boger, founder of Vertex, appointed Chair of CervoMed Board; RewinD-LB trial on track

## Summary
- Joshua Boger, Ph.D., former CEO and founder of Vertex Pharmaceuticals, appointed as director and Chair of CervoMed Board effective Feb 7, 2024.
- CervoMed expects to fully enroll RewinD-LB Phase 2b trial in 1H 2024; topline data for neflamapimod in DLB expected in 2H 2024.
- Boger beneficially owns 561,309 shares (~9.90% of CRVO) and pre-funded warrants for 495,995 shares.
- Dr. Sylvie Gregoire steps down as Chair but remains on Board.
- Boger will receive 10,000 stock option grant and standard non-employee director compensation.

## SEC filing metadata
- accession: 0001437749-24-003357
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2024-02-07T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774924003357/0001437749-24-003357-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774924003357/crvo20240205_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-003357
- JSON: https://secwatch.observer/filing/0001437749-24-003357.json
- Plain text: https://secwatch.observer/filing/0001437749-24-003357.txt

## Key facts
- Executive change
  Joshua S. Boger was appointed as Chair of the Board at CervoMed Inc..
  - Action: appointed
  - Role: Chair of the Board
  source text: On February 5, 2024, the Board of Directors (the “Board”) of CervoMed Inc. (the “Company”) appointed Joshua S. Boger, Ph.D., as a director of the Company and as Chair of the Board, effective February 7, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1053691/000143774924003357/0001437749-24-003357-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.